Composition and methods for the treatment of proliferative diseases
Methods and compositions are provided for treating proliferative disorders, wherein the composition comprises at least one compound according to Formula I: wherein R 1 is selected from the group consisting of —OH, —NH 2 , —NH—CH 2 —CO 2 H, —NH—CH(CH 3 )—CO 2 H, and —NH—C(CH 3 ) 2 —CO 2 H, or a pharmaceutically acceptable salt of such a compound; and an anthracycline, e.g. doxorubicin, or a pharmaceutically acceptable salt thereof, or a platin, e.g. oxaliplatin, or a pharmaceutically acceptable salt thereof.
1. A composition comprising (E)-2-(5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenylamino)acetic acid or a pharmaceutically acceptable salt thereof, and at least one chemotherapeutic agent selected from the group consisting of oxaliplatin, doxorubicin, and pharmaceutically acceptable salts thereof.
2. A composition according to claim 1 , wherein the at least one chemotherapeutic agent is doxorubicin, or a pharmaceutically acceptable salt thereof.
3. A composition according to claim 1 , wherein the at least one chemotherapeutic agent is oxaliplatin.
4. A composition according to claim 1 , comprising a sodium salt of (E)-2-(5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenylamino)acetic acid.
5. A method of treating an individual for a cancer comprising administering to the individual an effective amount of at least one composition according to claim 1 .
6. A method of treating an individual for a cancer comprising administering to the individual an effective amount of at least one composition according to claim 2 .
7. A method according to claim 5 , wherein the cancer is selected from the group consisting of ovarian cancer, cervical cancer, breast cancer, liver cancer, prostate cancer, testicular cancer, lung cancer, renal cancer, colorectal cancer, skin cancer, brain cancer and leukemia.
8. A method of treating an individual for a cancer comprising administering to the individual an effective amount of at least one composition according to claim 3 .
9. A method of treating an individual for a cancer proliferative disorder comprising administering to the individual an effective amount of (E)-2-(5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenylamino)acetic acid or a pharmaceutically acceptable salt thereof; and an effective amount of at least one chemotherapeutic agent selected from the group consisting of oxaliplatin, doxorubicin, and pharmaceutically acceptable salts thereof.
10. A method according to claim 9 , wherein the at least one chemotherapeutic agent is doxorubicin, or a pharmaceutically acceptable salt thereof.
11. A method according to claim 9 , wherein the at least one chemotherapeutic agent is oxaliplatin.
12. A method according to claim 9 , comprising administering to a to the individual an effective amount of a sodium salt of (E)-2-(5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenylamino)acetic acid.
13. A method according to claim 9 , wherein the cancer is selected from the group consisting of ovarian cancer, cervical cancer, breast cancer, liver cancer, prostate cancer, testicular cancer, lung cancer, renal cancer, colorectal cancer, skin cancer, brain cancer and leukemia.
14. A kit comprising, in a first compartment, (E)-2-(5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenylamino)acetic acid or a pharmaceutically acceptable salt thereof; and, in a second compartment, a chemotherapeutic agent selected from the group consisting of oxaliplatin, doxorubicin, and pharmaceutically acceptable salts thereof.
15. A kit according to claim 14 , wherein the at least one chemotherapeutic agent is doxorubicin, or a pharmaceutically acceptable salt thereof.
16. A kit according to claim 14 , wherein the at least one chemotherapeutic agent is oxaliplatin.
17. A kit according to claim 14 , comprising a sodium salt of (E)-2-(5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenylamino)acetic acid in the first compartment.
18. The method according to claim 9 wherein the (E)-2-(5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenylamino)acetic acid or pharmaceutically acceptable salt thereof and the at least one chemotherapeutic agent are administered concomitantly.